MedAvail (MDVLQ) 10-K 27 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Mar. 27, 2019	Jun. 29, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	MYOS RENS TECHNOLOGY INC.
Entity Central Index Key	0001402479
Trading Symbol	MYOS
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Ex Transition Period	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 11.3
Entity Common Stock, Shares Outstanding		9,165,578

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash	$ 15	$ 923
Accounts receivable, net	78	4
Other receivable	1,124
Inventories, net	1,676	1,779
Prepaid expenses	10	113
Total current assets	2,903	2,819
Other asset	50	50
Deferred offering costs	108	102
Fixed assets, net	149	184
Intangible assets, net	1,245	1,640
Total assets	4,455	4,795
Current liabilities:
Accounts payable	236	176
Accrued expenses and other current liabilities	383	255
Related party promissory note payable and accrued interest	1,015
Total current liabilities	1,634	431
Total liabilities	1,634	431
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 500,000 shares authorized; no shares issued and outstanding
Common stock, $.001 par value; 12,000,000 shares authorized at December 31, 2018 and 2017; 7,481,723 and 6,340,604 shares issued and outstanding at December 31, 2018 and 2017, respectively	8	6
Additional paid-in capital	37,880	36,202
Accumulated deficit	(35,067)	(31,844)
Total stockholders' equity	2,821	4,364
Total liabilities and stockholders' equity	$ 4,455	$ 4,795

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	12,000,000	12,000,000
Common stock, shares issued	7,481,723	6,340,604
Common stock, shares outstanding	7,481,723	6,340,604

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statements of Operations [Abstract]
Net revenues	$ 360	$ 526
Cost of sales	248	308
Gross profit	112	218
Operating expenses
Selling, marketing and research	894	822
Personnel and benefits	1,718	1,450
General and administrative	1,829	2,014
Total operating expenses	4,441	4,286
Operating loss	(4,329)	(4,068)
Other (expense) income
Other (expense) income	(2)	12
Interest expense	(16)	(2)
Total other (expense) income	(18)	10
Loss before income taxes	(4,347)	(4,058)
Income tax benefit	1,124
Net loss	$ (3,223)	$ (4,058)
Net loss per share attributable to common shareholders:
Basic and diluted	$ (0.45)	$ (0.69)
Weighted average number of common shares outstanding:
Basic and diluted	7,139,312	5,875,239

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated deficit
Balance at Dec. 31, 2016	$ 5,318	$ 5	$ 33,099	$ (27,786)
Balance, shares at Dec. 31, 2016		5,344,372
Proceeds from issuance of common stock, net	2,944	$ 1	2,943
Proceeds from issuance of common stock, net, shares		1,000,000
Shares forfeited by employees and directors
Shares forfeited by employees and directors, shares		(3,768)
Share-based compensation expense	160		160
Net loss	(4,058)			(4,058)
Balance at Dec. 31, 2017	4,364	$ 6	36,202	(31,844)
Balance, shares at Dec. 31, 2017		6,340,604
Proceeds from issuance of common stock, net	1,444	$ 1	1,443
Proceeds from issuance of common stock, net, shares		1,077,972
Share-based compensation expense	150		150
Shares issued to employees, directors and consultants	86	$ 1	85
Shares issued to employees, directors and consultants, shares		63,147
Net loss	(3,223)			(3,223)
Balance at Dec. 31, 2018	$ 2,821	$ 8	$ 37,880	$ (35,067)
Balance, shares at Dec. 31, 2018		7,481,723

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities:
Net loss	$ (3,223)	$ (4,058)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	35	51
Amortization	395	267
Provision for inventory reserve	25	2
Bad debt expense		59
Share-based compensation	235	160
Deferred offering costs	97
Changes in operating assets and liabilities:
Increase in accounts receivable	(74)	(55)
Increase in other current assets	(1,124)
Decrease in inventories	78	81
Decrease (increase) in prepaid expenses	103	(78)
Decrease in deferred revenue		(56)
Decrease in accounts payable and accrued expenses	203	(156)
Net cash used in operating activities	(3,250)	(3,783)
Cash Flows From Investing Activities:
Purchases of fixed assets		(2)
Net cash used in investing activities		(2)
Cash Flows From Financing Activities:
Proceeds from registered direct offering of common stock, net of costs	1,450	2,944
Deferred offering costs from at-the-market transaction	(108)	(102)
Proceeds from related party promissory note payable	1,000
Net cash provided by financing activities	2,342	2,842
Net decrease in cash	(908)	(943)
Cash at beginning of year	923	1,866
Cash at end of year	15	923
Cash paid during the year for:
Interest	1	2
Supplemental schedule of non-cash investing and financing activities:
Recognition of deferred offering costs as a reduction of equity in connection with the at-the-market offering	$ 6	$ 23

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Liquidity	12 Months Ended
	Dec. 31, 2018
Nature of Operations, Basis of Presentation and Liquidity [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY	NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND LIQUIDITY Nature of Operations MYOS RENS Technology Inc. is an emerging company focused on the discovery, development and commercialization of advanced nutrition products that improve muscle health and performance. The Company was incorporated under the laws of the State of Nevada on April 11, 2007. On March 17, 2016, the Company merged with its wholly-owned subsidiary and changed its name from MYOS Corporation to MYOS RENS Technology Inc. As used in these financial statements, the terms “the Company”, “MYOS”, “our”, or “we”, refers to MYOS RENS Technology Inc. and its subsidiary, unless the context indicates otherwise. On February 25, 2011, the Company entered into an agreement to acquire the intellectual property for Fortetropin ® Our commercial focus is to leverage our clinical data to develop multiple products to target the large, but currently underserved, markets focused on muscle health. The sales channels through which we sell our products are evolving. The first product we introduced was MYO-T12, which was sold in the sports nutrition market. MYO-T12 is a proprietary formula containing Fortetropin ® In February 2014, we expanded our commercial operations into the age management market through a distribution agreement with Cenegenics Product and Lab Services, LLC (“Cenegenics”), under which Cenegenics distributed and promoted a proprietary formulation containing Fortetropin ® In April 2015 we launched Rē Muscle Health, our own direct-to-consumer brand with a portfolio of muscle health bars, meal replacement shakes and daily supplement powders each powered by a full 6.6 gram single serving dose of Fortetropin ® In May 2016, we launched Physician Muscle Health Formula, a proprietary formulation containing Fortetropin ® In March 2017 we launched Qurr®, a Fortetropin ® ® In March 2018, we launched Yolked®, a Fortetropin®-powered product which is NSF Certified for Sports, and developed and marketed to collegiate and professional athletes who want to increase their muscle size and performance with an all-natural advanced nutrition product. The Company recorded $117 of net sales for the year ended December 31, 2018 for our Yolked® product line. In June 2018, we launched our Fortetropin ® of MCMF. We continue to pursue additional distribution and branded sales opportunities. There can be no assurance that we will be able to secure distribution arrangements on terms acceptable to us, or that we will be able to generate significant sales of our current and future branded products. We expect to continue developing our own core branded products in markets such as functional foods, sports and fitness nutrition and to pursue international sales opportunities. We remain committed to continuing our focus on various clinical trials in support of enhancing our commercial strategy as well as enhancing our intellectual property assets, to develop product improvements and new products, and to reduce the cost of our products by finding more efficient manufacturing processes and contract manufacturers. Strategic Investment Transaction On December 17, 2015, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with RENS Technology Inc. (the “Purchaser”), pursuant to which the Purchaser agreed to invest $20.25 million in the Company in three tranches (the “Financing”) in exchange for an aggregate of 3,537,037 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”). In the first tranche which closed on March 3, 2016 the Purchaser acquired 1,500,000 Shares and a warrant to purchase 375,000 shares of Common Stock (the “Initial Warrant”) for $5.25 million. On August 19, 2016, the Purchaser notified the Company that it did not intend to fulfill its obligation to fund the second tranche of the Financing in accordance with terms of the Purchase Agreement. On January 6, 2017, in connection with the financing contemplated by a securities purchase agreement with RENS Technology Inc. (the “Purchaser”), the Company commenced an action in the Supreme Court of New York, County of New York (the “Court”), against the Purchaser, RENS Agriculture, the parent company of the Purchaser, and Ren Ren, a principal in both entities and one of our directors, arising from the Purchaser’s breach of the aforementioned agreement. See NOTE 15 – LEGAL PROCEEDINGS. Going Concern and Liquidity The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), which contemplates continuation of the Company as a going concern. The Company has suffered recurring losses from operations and incurred a net loss of approximately $3,223 for the year ended December 31, 2018 and $4,058 for the year ended December 31, 2017. The Company has historically recorded minimal sales during the past eighteen (18) consecutive quarters. In June 2018, the Company launched a Fortetropin ® TM ® As of the filing date of this Report, management believes that there may not be sufficient capital resources from operations and existing financing arrangements in order to meet operating expenses and working capital requirements for the next twelve months, primarily due to the failure of RENS Technology Inc. to fund the required amounts. These facts raise substantial doubt about the Company’s ability to continue as a going concern. Accordingly, we are evaluating various alternatives, including reducing operating expenses, securing additional financing through debt or equity securities to fund future business activities and other strategic alternatives. There can be no assurance that the Company will be able to generate the level of operating revenues in its business plan, or if additional sources of financing will be available on acceptable terms, if at all. If no additional sources of financing are available, our future operating prospects may be adversely affected. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. At-the-Market Offering On February 21, 2017, the Company entered into a sales agreement with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) which established an at-the-market equity program pursuant to which the Company may offer and sell up to $6.0 million of its shares of common stock from time to time through H.C. Wainwright. The Company incurred $125 of deferred offering costs in connection with this program which were originally recorded as a long term other asset on the Company’s consolidated balance sheets. Since this sales agreement expired by June 30, 2018 the remaining deferred offering costs of $96 were recognized and recorded within the accompanying consolidated statements of operations as general and administrative expenses for the year ended December 31, 2018. On October 26, 2017, the Company sold 500,000 shares of common stock for $2.144 per share for gross proceeds of $1,070 in an at-the-market offering. On January 19, 2018, the Company sold 140,295 shares of common stock for $2.111 per share for gross proceeds of $296 in an at-the-market offering. On various dates in April 2018, the Company sold an aggregate of 131,225 shares of common stock at various prices for aggregate gross proceeds of $176 under the Company’s existing at-the-market program. On July 24, 2018, the Company entered into a new sales agreement with H.C. Wainwright which established a new at-the-market equity program pursuant to which the Company may offer and sell up to $1.6 million shares of common stock from time to time through H.C. Wainwright. The Company incurred $108 of deferred offering costs in connection with this program as of December 31, 2018 which was recorded as a long term other asset on the Company’s consolidated balance sheets. The deferred offering costs will be reflected as a reduction in equity as the Company incurs sales of its stock pursuant to this program. Management continues to evaluate the ongoing progress of this program and its related outstanding deferred offering costs. Subsequent to year end on January 15, 2019, the Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. As of the filing date of this Form 10-K, a total of 804,009 shares were sold under this program for aggregate gross proceeds of $1,609. Private Placement On April 25, 2018, the Company entered into a securities purchase agreement with private investors providing for the issuance and sale by the Company of 806,452 shares of common stock, in a private placement offering at a purchase price of $1.24 per share, for gross proceeds of $1,000 and net proceeds of $978. Promissory Note Payable On August 30, 2018, the Company executed an unsecured promissory note (the “Note”) in the principal amount of up to $750 in favor of Joseph Mannello, the Company’s chief executive officer (the “Lender”). On November 13, 2018, the Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. Pursuant to the Note, on August 30, 2018, the Lender advanced $500 of funds to the Company. On September 26, 2018, the Lender advanced an additional $250 of funds to the Company. On December 27, 2018, the Lender advanced an additional $250 of funds to the Company. The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty. The proceeds of the Note will be used by the Company for general working capital purposes. As of December 31, 2018, the Company accrued $15 of interest expense on the Note.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance to U.S. GAAP and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the consolidated financial statements included in this report. Principles of Consolidation The accompanying consolidated financial statements include the accounts of MYOS RENS Technology Inc. and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions have been eliminated in consolidation. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications did not have an impact on the reported results of operations. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities. The Company has recorded minimal sales to its distributors during the past eighteen consecutive quarters. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At December 31, 2018 and 2017, the Company had no cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. As part of our ongoing liquidity assessments management evaluates our cash, cash equivalents. The amount of funds held in bank can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities so the Company may at times have exposure to cash in excess of FDIC insured limits. Concentrations of Credit Risk, Significant Customers and Significant Supplier Management regularly reviews accounts receivable, and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Accounts receivable is non-interest bearing. Credit is issued to customers without collateral. If an account becomes delinquent management will review if a write off is appropriate. Expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the consolidated statements of operations. As part of our ongoing liquidity assessments, management evaluates our cash and cash equivalents. The amount of funds held in the bank can fluctuate due to the timing of receipts and payments during the ordinary course of business and other reasons, such as business-development activities. The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the FDIC. Management monitors the soundness of these institutions to minimize the Company’s risk. As a result, the Company may have exposure to cash in excess of FDIC insured limits. For the year ended December 31, 2018, the Company had a concentration of revenue with one major customer accounting for 21% of total revenue. For the year ended December 31, 2017, the Company had a concentration of revenue with one major customer accounting for 38 percent of total revenue. A loss of a major customer could have a material adverse effect on future operating results. As of December 31, 2018, accounts receivable from this major customer amounted to approximately 99% of total accounts receivable. For the year ended December 31, 2017 there were no receivables from a major customer. Failure to collect these receivables could have a material adverse effect on our future operating results. For the years ended December 31, 2018 and 2017, the Company purchased its raw material from one third party supplier. The Company believes alternative suppliers could be located in the event of a disruption in availability of goods from this supplier. The Company had the following concentrations of accounts receivable with customers: December 31, 2018 2017 Direct-to-consumer $ 78 $ 4 Related party sale - 59 Subtotal 78 63 Allowance for doubtful accounts - (59 ) Accounts receivable, net $ 78 $ 4 The Company had the following concentrations of revenues with customers: December 31, 2018 2017 Cenegenics - 38 % Vitamin Shoppe 21 % - Inventories, net Inventories are valued at the lower of cost or net realizable value, with cost determined on a first in, first-out basis. Each quarter the Company evaluates the need for a change in the inventory reserve based on sales and expiration dates of products. As of December 31, 2018, all expired product had been fully reserved and removed from inventory. Fixed Assets Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset’s useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the Consolidated Statements of Operations. Repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method for all fixed assets. We review our fixed assets for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. We did not consider any of our fixed assets to be impaired during the years ended December 31, 2018 and 2017. Deferred Offering Costs The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering not be completed, deferred offering costs are charged to operations during the period in accordance with SEC guidance. Since the February 21, 2017 sales agreement expired by June 30, 2018, the remaining deferred offering costs of $96 on the Company’s consolidated balance sheets were recognized and recorded within the Company’s consolidated statements of operations as general and administrative expenses for the year ended December 31, 2018. On July 24, 2018, the Company entered into a new sales agreement, incurring $108 of deferred offering costs as of December 31, 2018 which was recorded as a long term other asset on the accompanying consolidated balance sheet. Intangible Assets The Company’s intangible assets consist primarily of intellectual property pertaining to Fortetropin ® In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin ® In March 2017, the Company launched a new product line Qurr® and a related website qurr.com. The Company capitalized $380 of the costs to build the website in accordance with U.S. GAAP and initially amortized this asset over 60 month’s useful life to March 2022. As of December 31, 2018 the company accelerated the amortization of this asset to December 31, 2019 to mirror the expiration date of the remaining Qurr® in its inventory. Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Intangible assets at December 31, 2018 and December 31, 2017 consisted of the following: December 31, December 31, 2018 2017 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization - intellectual property (994 ) (784 ) Less: accumulated amortization - website (242 ) (57 ) Total intangibles with finite lives 1,245 1,640 Intangibles with indefinite lives - - Total intangible assets, net $ 1,245 $ 1,640 Amortization expense related to intangible assets for the years ended December 31, 2018 and 2017 was $395 and $267. Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted, undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value. Based on eighteen consecutive quarters of minimal revenues combined with changes in the sales channels through which the Company sells its products and an inability to predict future orders, if any, we tested the intellectual property for impairment in the fourth quarter of 2018 and determined that the asset value was recoverable and therefore no impairment was recognized. We did not have any impairment losses recorded during the years ended December 31, 2018 and 2017, respectively. Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be as follows: (In thousand $) Years Ended December 31, Amount 2019 $ 345 2020 200 2021 200 2022 200 2023 200 2024 100 Total $ 1,245 Fair Value of Long-Lived Assets We test long-lived assets, including fixed assets and intangibles with finite lives, for recoverability when events or changes in circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. We consider historical performance and future estimated results in our evaluation of potential impairment and then compare the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, we measure the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate we utilize to evaluate potential investments. We estimate fair value based on the information available in making the necessary estimates, judgments and projections. Revenue Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 (“ASU 2014-09”), as amended, using the modified retrospective method. ASU 2014-09, which is codified in the FASB Accounting Standards Codification as Topic 606, Revenue from Contracts with Customers, The adoption of ASU 2014-09 did not impact the Company’s timing or amounts of revenue recognition. As such, the Company recorded no transition adjustment as of January 1, 2018. However, the additional required qualitative and quantitative disclosures to Topic 606 are provided below. Revenue Recognition Net revenues include products and shipping and handling charges, net of estimates for incentives and other sales allowances or discounts. Our product sales generally do not provide for rights of return. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at the point in time the customer obtains control of the products. We consider charges associated with shipping and handling activities as costs to fulfill our performance obligations. Using probability assessments, we estimate sales incentives expected to be paid over the term of the contract. The majority of our contracts have a single performance obligation and are short term in nature. Sales taxes that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Disaggregation of Revenue Our net revenues by product type are presented below for the year ended December 31, 2018 and 2017. Twelve-month Period Product Type December 31, December 31, Qurr® (1) $ 175 $ 164 Yolked® (2) 117 - Myos Canine Muscle Formula® (3) 44 - Physician Muscle Health Formula (4) 24 24 Cenegenics (5) - 200 Egg Yolk Powder (6) - 116 Rē Muscle Health (6) - 22 Total Net Revenues $ 360 $ 526 (1) Qurr® product was launched in March 2017 (2) Yolked® product was launched in March 2018 (3) Myos Canine Muscle Formula® was launched in June 2018 (4) Physician’s Muscle Health Formula was launched in May 2016 (5) Cenegenics is a Fortetropin ® (6) Egg Yolk Powder and Rē Muscle Health products were no longer available after 2017 Advertising The Company charges the costs of advertising to sales and marketing expenses as incurred. Advertising and marketing costs were $308 and $267 for the years ended December 31, 2018 and 2017, respectively. For the year ended December 31, 2018, advertising costs consisted primarily of marketing costs for our new products Yolked® and Myos Canine Muscle Formula®. For the year ended December 31, 2017, advertising costs consisted primarily of marketing costs for our Qurr® line of products. Shipping and Handling Costs The Company records costs for the shipping and handling of products to our customers in cost of sales. These expenses were $48 and $37 for the years ended December 31, 2018 and 2017, respectively. Research and Development Research and development expenses consist primarily of the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed. During the years ended December 31, 2018 and 2017, the Company incurred research and development expenses of $417 and $240 respectively. These included payments to DIL for research of $150 and $210 for the years ended December 31, 2018 and 2017. Share-based Compensation Share-based payments are measured at their estimated fair value on the date of grant. Share-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Share-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of the fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate. Segment Information Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchy levels of inputs to measure fair value: Level 1 Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Level 3: Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At December 31, 2018 and 2017, the Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values. Basic and Diluted Loss per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the years ended December 31, 2018 and 2017, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at December 31, 2018 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,083,082, which includes warrants to purchase an aggregate 821,202 shares of common stock, options to purchase an aggregate of 261,880 shares of common stock and rights under the Rights Agreement. The aggregate number of potentially dilutive common stock equivalents outstanding at December 31, 2017 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,067,332, which includes warrants to purchase an aggregate 821,202 shares of common stock, options to purchase an aggregate of 244,880 shares of common stock, and unvested restricted stock awards of 1,250 shares of common stock. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes The Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017. The Tax Act contains several key provisions including, among other things, reducing the U.S. federal corporate tax rate from thirty-five percent to twenty-one percent. Changes in tax law are accounted for in the period of enactment. In addition, Federal net operating losses (“NOL”) generated during future periods will be carried forward indefinitely, but will be subject to an eighty percent utilization against taxable income. The carryback provision has been revoked for NOL after January 1, 2018. Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company’s financial statements. For the years ended December 31, 2018 and 2017, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business. The Company continues to evaluate the impact of the Tax Act and analyze additional guidance.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2018
Recent Accounting Pronouncements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 3 – RECENT ACCOUNTING PRONOUNCEMENTS In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019 with early adoption permitted, including in an interim period for which financial statements have not been issued or made available for issuance. The Company has evaluated the impact of early adoption of this ASU and determined that it will not have a significant impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The new guidance expands the scope of Topic 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations, and supersedes the guidance in ASC 505-50, Equity-Based Payments to Non-Employees. The most significant change resulting from this update is that stock-based awards granted to non-employees will no longer need to be re-measured at fair value at each financial reporting date until performance is complete, as these awards will be measured at fair value at the grant date. The guidance is effective January 1, 2019 with early adoption permitted, including in an interim period for which financial statements have not been issued. The Company has evaluated the impact of early adoption of this ASU and determined that it will not have a significant impact on its consolidated financial statements. In March 2018, the FASB issued ASU 2018-5 – Income Taxes (Topic 740): Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 118. This ASU provided guidance related to Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 118 (“SAB 118”), which addresses the accounting implications of the Tax Act. SAB 118 allows a company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date and was effective upon issuance. We have analyzed the Tax Act, and in certain areas, have made reasonable estimates of the effects on our consolidated financial statements and tax disclosures. In September 2017, the FASB issued ASU No. 2017-13, Revenue from Contracts with Customers which amended FASB Accounting Standards Codification® (ASC) by creating Topic 606, Revenue from Contracts with Customers. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (“ASU 2014-09”). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The FASB also issued the following amendments to ASU No. 2014-09 to provide clarification on the guidance: ● ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606) – Deferral of the Effective Date ● ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606) – Principal versus Agent (Reporting Revenue Gross vs. Net) ● ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606) – Identifying Performance Obligations and Licensing ● ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606) – Narrow-Scope Improvements and Practical Expedients The adoption of Topic 606 is required for public entities for reporting periods beginning after December 15, 2017. The Company has adopted the provisions of this ASU for its fiscal year beginning January 1, 2018 using the modified retrospective transition method. This method involves application of the new guidance to either: (a) all contracts at the date of initial application or (b) only contracts that are not completed at the date of initial application. Under this method, if necessary, a cumulative effect adjustment is recognized as of the date of initial application. The adoption of ASU 2014-09 did not have an impact on the Company, therefore, no cumulative effect adjustment was required. In May 2017, the FASB issued ASU No. 2017-09, Compensation – Stock Compensation (Topic 718). The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This update is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. Th is accounting guidance was effective for us beginning January 1, 2018. The Company has evaluated the impact of the updated guidance and has determined that the adoption of ASU 2017-09 did not have a significant impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Simplifying the Test for Goodwill”, which accomplishes exactly what its title indicates by eliminating the second step in the current goodwill impairment calculation. Currently there is a two-step process for determining the amount of any goodwill impairment. In Step 1 an entity determines if the carrying value of the reporting unit (for which goodwill has been recorded) exceeds the fair value of the reporting unit. If the calculation in Step 1 indicates that the carrying value of a reporting unit for which goodwill has been recorded exceeds the fair value, the entity would have to determine the implied fair value of the reporting unit’s goodwill. An impairment would be recorded to the extent that the goodwill carrying value exceeded the implied fair value of goodwill at the reporting date. The amount of any goodwill impairment must take into consideration the effects of income taxes for any tax deductible goodwill. The effective date to adopt the ASU is for fiscal years beginning after December 15, 2019. The ASU is to be applied prospectively. Early adoption is permitted. The Company has evaluated the impact of the updated guidance and has determined that the adoption of ASU 2017-04 is not expected to have a significant impact on its consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force).” The amendments in this Update relate to eight specific types of cash receipts and cash payments which current U.S. GAAP either is unclear or does not include specific guidance on the cash flow classification issues. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company has adopted the provisions of this ASU for its fiscal year beginning January 1, 2018. The adoption of ASU 2016-15 did not have a significant impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which requires lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee will continue to primarily depend on its classification as a finance or operating lease. However, unlike current U.S. GAAP, which requires only capital leases to be recognized on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU 2016-02 also requires disclosures about the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the financial statements. ASU 2016-02 is effective beginning January 1, 2019, with early application permitted. In July 2018, the FASB issued ASU No. 2018-11, which provides targeted improvements to the new lease standard, including an option to apply the transition provisions at its adoption date instead of at the earliest comparative period presented in its financial statements. We have evaluated the adoption of ASU 2016-02 and determined that the standard did not have a significant impact on the Company’s consolidated financial statements.

Inventories, Net

Inventories, Net	12 Months Ended
	Dec. 31, 2018
Inventories, Net [Abstract]
INVENTORIES, NET	NOTE 4 – INVENTORIES, NET Inventories, net at December 31, 2018 and 2017 consisted of the following: (In thousands $) December 31, December 31, Raw materials $ 1,769 $ 2,223 Work in process 37 64 Finished goods 135 203 1,941 2,490 Less: inventory reserves (265 ) (711 ) Inventories, net $ 1,676 $ 1,779

Fixed Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2018
Fixed Assets [Abstract]
FIXED ASSETS	NOTE 5 – FIXED ASSETS Fixed assets at December 31, 2018 and 2017 consisted of the following: (In thousands $) December 31, December 31, Furniture, fixtures and equipment $ 116 $ 116 Computers and software 68 68 Leasehold improvements 239 239 Other 7 7 Total fixed assets 430 430 Less: accumulated depreciation and amortization (281 ) (246 ) Net book value of fixed assets $ 149 $ 184 Depreciation expense was $35 and $51 for the years ended December 31, 2018 and 2017, respectively. Repairs and maintenance costs are expensed as incurred.

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2018
Prepaid Expenses [Abstract]
PREPAID EXPENSES	NOTE 6 – PREPAID EXPENSES Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. Prepaid expenses at December 31, 2018 and 2017 consisted of the following: (In thousands $) December 31, December 31, Prepaid insurance $ - $ 88 Prepaid consulting and other 10 25 Total prepaid expenses $ 10 $ 113

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2018
Accrued Expenses and Other Current Liabilities [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 7 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of estimated future payments that relate to the current and prior accounting periods. Management reviews these estimates regularly to determine their reasonableness. Accrued expenses and other current liabilities at December 31, 2018 and 2017 consisted of the following: (In thousands $) December 31, December 31, Professional fees $ 85 $ 151 Accrued board compensation 181 Research and development 91 - Insurance premium financing - 66 Deferred rent 10 19 Other accrued expenses 16 19 Total accrued expenses $ 383 $ 255

Related Party Promissory Note a

Related Party Promissory Note and Accrued Interest	12 Months Ended
	Dec. 31, 2018
Related Party Promissory Note and Accrued Interest [Abstract]
RELATED PARTY PROMISSORY NOTE AND ACCRUED INTEREST	NOTE 8 – RELATED PARTY PROMISSORY NOTE AND ACCRUED INTEREST In August 2018 the Company issued an unsecured promissory note (the “Note”) in the principal amount of $750 in favor of Joseph Mannello, the Company’s chief executive officer (the “Lender”). This Note was approved by the Company’s board of directors (the “Board”). Pursuant to the Note, on August 30, 2018, the Lender advanced $500 of funds to the Company. On September 26, 2018, the Lender advanced an additional $250 of funds to the Company. On November 13, 2018, the Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. On November 19, 2018, the Lender advanced an additional $250 of funds to the Company. As of December 31, 2018 the Company recorded $1,000 as a liability on the consolidated balance sheets. The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty. The proceeds of the Note will be used by the Company for general working capital purposes. As of December 31, 2018 the Company accrued $15 of interest expense on the Note. Subsequent to year end, on March 20, 2019, the Company entered into a securities purchase agreement with a group of accredited investors, including two members of the Company’s board of directors, in a private placement for aggregate gross proceeds of $2.1 million, which includes the conversion of $250 of the principal amount of a $1.0 million promissory note previously issued by the Company to its chief executive officer.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 9 – STOCKHOLDERS’ EQUITY Preferred Stock Rights Effective February 14, 2017, the Board declared a dividend of one Right for each of the Company’s issued and outstanding shares of common stock. The Rights were granted to the stockholders of record at the close of business on February 24, 2017. Each Right entitles the registered holder, upon the occurrence of certain events specified in the Rights Agreement, to purchase from the Company one one-thousandth of a share of the Company’s Series A Preferred Stock at a price of $7.00, subject to certain adjustments. The Rights are not exercisable until the occurrence of certain events, including a person acquiring or obtaining the right to acquire beneficial ownership of 10% or more of the Company’s outstanding common stock. The Rights are evidenced by certificates for the common stock and automatically transfer with the common stock unless they become exercisable. If the Rights become exercisable, separate certificates evidencing the Rights will be distributed to each holder of common stock. Holders of the preferred stock will be entitled to certain dividend, liquidation and voting rights. The rights are redeemable by the Company at a fixed price as determined by the Board, after certain defined events. As of December 31, 2018, the Rights have no dilutive effect on the earnings per common share calculation and no shares of preferred stock have been issued. The Company has determined that these rights have a de minimis fair value. The description and terms of the Rights are set forth in the Rights Agreement dated as of February 14, 2017 between the Company and Island Stock Transfer, as Rights Agent. Issuance of Common Stock The Company has periodically issued common stock in connection with certain private and public offerings. For the years ended December 31, 2018 and 2017 the Company has received aggregate gross proceeds of $1,472 and $3,197 from these offerings: Gross Date Shares Proceeds April 29, 2018 806,452 (1) $ 1,000 April 4 – April 23, 2018 131,225 (2) 176 January 19, 2018 140,295 (3) 296 October 31, 2017 500,000 (4) 1,072 February 8, 2017 500,000 (5) 2,125 Total 2,077,972 $ 4,669 (1) Shares issued pursuant to a private placement with accredited investors for $1.24 per share. (2) Shares of common stock sold for between $1.25 and $1.38 per share in an at-the-market offering. (3) Shares of common stock sold for $2.111 per share in an at-the-market offering. (4) Shares of common stock sold for $2.144 per share in an at-the-market offering. (5) Shares issued pursuant to a registered direct offering with an institutional investor for $4.25 per share. In addition, the Company issued 55,147 shares of restricted common stock under its 2012 equity incentive plan in January 2018 valued at $65,000 as Board compensation for 2017. Registered Direct Offering On February 3, 2017, the Company entered into a securities purchase agreement with an institutional investor providing for the issuance and sale by the Company of 500,000 shares of common stock, in a registered direct offering at a purchase price of $4.25 per share, for gross proceeds of $2,125. The offering closed on February 8, 2017. Offering costs of $199 were recognized as an offset to additional paid in capital. At-the-Market Offering On February 21, 2017, the Company entered into a sales agreement with H.C. Wainwright & Co., LLC (“H.C. Wainwright”) which established an at-the-market equity program pursuant to which the Company may offer and sell up to $6.0 million of its shares of common stock from time to time through H.C. Wainwright. The Company incurred $125 of deferred offering costs in connection with this program which were originally recorded as a long term other asset on the Company’s consolidated balance sheets. Since this sales agreement expired by June 30, 2018 the remaining deferred offering costs of $96 were recognized and recorded within the accompanying consolidated statements of operations as general and administrative expenses for the year ended December 31, 2018. On October 26, 2017, the Company sold 500,000 shares of common stock for $2.144 per share for gross proceeds of $1,072 in an at-the-market offering . On January 19, 2018, the Company sold 140,295 shares of common stock for $2.111 per share for gross proceeds of $296 in an at-the-market offering. On various dates in April 2018, the Company sold an aggregate of 131,225 shares of common stock at various prices for aggregate gross proceeds of $176 under the Company’s existing at-the-market program. On July 24, 2018, the Company entered into a new sales agreement with H.C. Wainwright which established a new at-the-market equity program pursuant to which the Company may offer and sell shares of common stock from time to time through H.C. Wainwright up to $1.6 million worth. The Company incurred $108 of deferred offering costs in connection with this program as of December 31, 2018 which was recorded as a long term other asset on the Company’s consolidated balance sheets. The deferred offering costs will be reflected as a reduction in equity as the Company incurs sales of its stock pursuant to this program. Management continues to evaluate the ongoing progress of this program and its related outstanding deferred offering costs. Subsequent to year end on January 15, 2019 the Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019 the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $145 in an at-the-market offering. As of the filing date of this Form 10-K, a total of 882,649 shares were sold under these programs for aggregate gross proceeds of $1,755. Private Placement On April 25, 2018, the Company entered into a securities purchase agreement with private investors providing for the issuance and sale by the Company of 806,452 shares of common stock, in a private placement offering at a purchase price of $1.24 per share, for gross proceeds of $1,000 and net proceeds of $978.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Warrants [Abstract]
WARRANTS	NOTE 10 – WARRANTS The following table summarizes information about outstanding and exercisable warrants at December 31, 2018: Shares Number of Underlying Shares Shares Warrants Underlying Underlying Exchanged, Warrants Warrants Exercised Outstanding Expiration Originally or and Exercise Term Description Grant Date Granted or Expired Exercisable Price in years Series B (1) January 27, 2014 157,846 - 157,846 $ 45.00 0.07 Series C (2) November 19, 2014 145,399 (142,957 ) 2,442 $ 12.00 1.38 Repricing Series C (2) November 19, 2014 142,957 142,957 $ 9.00 1.38 Repricing Series E (2) November 19, 2014 142,957 142,957 $ 9.00 3.38 Rens (3) March 3, 2016 375,000 - 375,000 $ 7.00 1.06 678,245 142,957 821,202 (1) Issued in connection with the January 27, 2014 private placement transaction. (2) Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015. (3) Shares issued pursuant to the closing of the first tranche of the financing with RENS Technology Inc.

Stock Compensation

Stock Compensation	12 Months Ended
	Dec. 31, 2018
Stock Compensation [Abstract]
STOCK COMPENSATION	NOTE 11 – STOCK COMPENSATION Equity Incentive Plan The Company increased the number of shares available for issuance under its 2012 Equity Incentive Plan (as amended, the “Plan”) from 550,000 to 850,000 in November 2016, which was approved by the Company’s shareholders in December 2016. The plan provides for the issuance of up to 850,000 shares. The Plan provides for grants of stock options, stock appreciation rights, restricted stock, other stock-based awards and other cash-based awards. As of December 31, 2018, the remaining shares of common stock available for future issuances of awards was 251,260. The Company granted an aggregate of 30,000 options to purchase restricted common stock to certain directors prior to the adoption of the Plan. Stock options generally vest and become exercisable with respect to 100% of the common stock subject to such stock option on the third (3rd) anniversary of the date of grant. Any unvested portion of a stock option shall expire upon termination of employment or service of the participant granted the stock option, and the vested portion shall remain exercisable in accordance with the provisions of the Plan. Stock Options The following table summarizes stock option activity for the years ended December 31, 2018 and 2017: Weighted Weighted Average Shares Average Remaining Under Exercise Contractual Options Price Term (Years) Balance at December 31, 2016 300,340 $ 15.09 6.71 Options granted 300,000 4.00 Options forfeited (38,600 ) 7.15 Balance at December 31, 2017 561,740 $ 7.32 5.61 Options granted 57,000 $ 4.00 Options forfeited (20,000 ) 4.00 Balance at December 31, 2018 598,740 $ 6.76 5.65 The weighted average grant date fair value of stock options granted during 2018 was $1.25. The following table summarizes the assumptions used to value stock options granted in 2018 and 2017 using a Black-Scholes model: 2018 2017 Risk-free interest rate 2.38 % 2.19 % Expected volatility 100 % 100 % Expected forfeiture rate 0 % 0 % Expected term (years) 6.0 6.0 Expected dividend yield 0 % 0 % The risk-free rate is based on the U.S. Treasury rate for a note with a similar term in effect at the time of the grant. The expected volatility is based on the volatility of the Company’s historical stock prices. At December 31, 2018 and 2017, the exercisable options had no intrinsic value. The following table summarizes information about options outstanding and exercisable at December 31, 2018 that were granted under the Plan: Options Outstanding Options Exercisable Weighted Average Weighted Average Exercise Options Remaining Exercise Options Remaining Price Outstanding Contractual Life Price Exercisable Contractual Life $ 4.00 337,000 9.00 $ 4.00 17,000 9.00 $ 8.60 16,000 5.19 $ 8.60 16,000 5.19 $ 10.00 40 3.89 $ 10.00 40 3.89 $ 12.10 30,000 5.35 $ 12.10 30,000 5.35 $ 12.50 81,700 5.42 $ 12.50 67,278 5.42 $ 13.45 2,000 5.47 $ 13.45 1,000 5.47 $ 13.50 12,000 5.49 $ 13.50 10,562 5.49 $ 17.50 100,000 4.11 $ 17.50 100,000 4.11 $ 32.00 15,000 2.54 $ 32.00 15,000 2.54 $ 34.50 5,000 2.57 $ 34.50 5,000 2.57 598,740 261,880 As of December 31, 2018, 261,880 options have vested and 336,860 options remain unvested. The vesting terms range from 4.5 to 9.0 years and the vested options have a weighted average remaining term of 5.7 years and a weighted average exercise price of $15.7 per share. Restricted Stock The following table summarizes restricted stock awards activity for the years ended December 31, 2018 and 2017: Weighted Average Grant Date Shares Share Price Restricted stock awards unvested at December 31, 2016 53,857 $ 2.74 Vested (46,607 ) 5.17 Forfeited (6,000 ) 1.75 Restricted stock awards unvested at December 31, 2017 1,250 1.02 Granted 63,137 1.36 Vested (64,387 ) 1.30 Restricted stock awards unvested at December 31, 2018 - $ - At December 31, 2018, there were no unvested restricted stock awards. Share-Based Compensation Share-based compensation was $235 and $160 for the years ended December 31, 2018 and 2017, respectively. Share-based compensation consists of expenses related to the issuance of stock options and restricted stock. There was no unrecognized compensation expense of stock options and restricted stock at December 31, 2018.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
INCOME TAXES	NOTE 12 – INCOME TAXES Income tax expense for the years ended December 31, 2018 and 2017 is shown as follows: December 31, December 31, (In thousand $) 2018 2017 Current provision $ (1,124 ) $ - Deferred provision - - Total tax provision (benefit) $ (1,124 ) $ - The significant components of the Company’s deferred tax assets and liabilities at December 31, 2018 and 2017 are as follows: December 31, December 31, (In thousand $) 2018 2017 Federal net operating losses $ 5,669 $ 5,029 State net operating losses 31 886 Stock options 646 701 Federal tax credit 190 190 Amortization 198 283 Depreciation 20 (3 ) Accrued expenses 4 - Contributions 10 14 Other 62 194 Total gross deferred tax assets/(liabilities) 6,830 7,294 Less valuation allowance (6,830 ) (7,294 ) Net deferred tax assets/(liabilities) $ - $ - On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (“Tax Reform Legislation”), which made significant changes to U.S. federal income tax law. The Company expects that certain aspects of the Tax Reform Legislation will positively impact the Company’s future after-tax earnings primarily due to the lower federal statutory tax rate. Beginning January 1, 2018, the Company’s U.S. income will be taxed at a 21 percent federal corporate rate. Further, we are required to recognize the effect of this rate change on our deferred tax assets and liabilities, and deferred tax asset valuation allowances in the period the tax rate change is enacted. The income tax benefit for the year ended December 31, 2018 differed from the amounts computed by applying the U.S. federal income tax rate of 21% to loss before tax benefit as a result of nondeductible expenses, tax credits generated, utilization of net operating loss carryforwards, increases in the Company’s valuation allowance, and the benefit received from the sale of New Jersey net operating losses. December 31, December 31, (In thousand $) 2018 2017 Federal statutory tax benefit $ (676 ) $ (852 ) Sale of NJ NOL credits (1,124 ) - Permanent differences 30 35 Research & development - (42 ) State taxes 2 1 True up 54 - Valuation allowance 591 (2,307 ) Effective tax rate dollars $ (1,123 ) $ (3,165 ) Effective tax rate percentage 34.74 % 77.98 % A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of the available evidence, both positive and negative, the Company determined that valuation allowances of $6.8 million and $7.3 million at December 31, 2018 and 2017, respectively, were necessary to reduce the deferred tax assets to the amount that will more likely than not be realized. At December 31, 2018 and 2017, the Company had approximately $26.9 million and $23.7 million, respectively, of gross federal net operating loss carry-forwards, respectively. If not utilized, the federal and state net operating loss carry-forwards will begin to expire in 2027. The utilization of such net operating loss carry-forwards and realization of tax benefits in future years depends predominantly upon having taxable income. The Company also has $190 of federal research and development credits which will begin to expire in 2033 if not utilized. In November 2018 the Company received approval to sell a portion of its state net operating losses through the State of New Jersey Economic Development Authority (NJEDA) Technology Business Tax Certificate Program. In January 2019 the Company received net proceeds of $1,124 from the sale of its net operating losses. The Company plans to apply to sell additional net operating losses under the same program in 2019. The Company may be subject to the net operating loss provisions of Section 382 of the Internal Revenue Code. The Company has not calculated if an ownership change has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company’s capital during a specified period, and the federal published interest rate. Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2018 there were no uncertain positions. The federal and state income tax returns of the Company for 2014, 2015, 2016 and 2017 are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. There was no income tax related interest and penalties included in the income tax provision for 2018 and 2017.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES Operating Lease The Company leases its corporate offices under an operating lease. The term of the lease is five years commencing on January 1, 2015 and expiring on December 31, 2019. The Company has two options to renew its lease for an additional three years each. At December 31, 2018 , the future minimum lease payments under the non-cancellable operating lease in excess of one year is as follows: (In thousand $) Years Ended December 31, Amount 2019 $ 72 Total $ 72 Rent expense including common area maintenance charges and taxes for the years ended December 31, 2018 and 2017 was $79 and $68, respectively. Defined Contribution Plan The Company established a 401(K) Plan (the “401(K) Plan”) for eligible employees of the Company effective April 1, 2014. Generally, all employees of the Company who are at least twenty-one years of age and who have completed three months of service are eligible to participate in the 401(K) Plan. The 401(K) Plan is a defined contribution plan that provides that participants may make salary deferral contributions, of up to the statutory maximum allowed by law (subject to catch-up contributions) in the form of voluntary payroll deductions. The Company’s matching contribution is equal to 100 percent on the first four percent of a participant’s compensation which is deferred as an elective deferral. The Company’s aggregate matching contributions were $33 and $26 for the years ended December 31, 2018 and 2017 , respectively. Clinical and Basic Research Programs The Company invests in research and development activities externally through academic and industry collaborations aimed at enhancing the Company’s products and optimizing manufacturing. At December 31, 2018, the future minimum payments for collaborations with various academic centers is as follows: Years Ended December 31, Amount 2019 $ 91 2020 102 Total $ 193 Supply Agreement On November 18, 2016, the Company entered into an Amended Supply Agreement with DIL Technologie GmbH (“DIL”). Pursuant to the agreement (and so long as the agreement is effective), DIL will manufacture and supply the Company with Fortetropin ® ® The Company agreed, commencing January 2017, to pay DIL €10 (approximately USD $12) per month for collaborative research. For the years ended December 31, 2018 and 2017 the Company paid USD $150 and $194 to DIL for collaborative research. The monthly payments terminate upon the earlier of: (a) the date that the Company orders additional product in accordance with the terms of the agreement and (b) December 31, 2018, and the Company has no further financial obligations to DIL thereafter. The Company also agreed to pay DIL €400 (approximately USD $480) in satisfaction of all prior liabilities and obligations under its prior agreements with DIL. The agreement expired on December 31, 2018, and the Company has not elected to renew the agreement as of the date of the filing of this 10-K report. Product Liability As a manufacturer of nutritional supplements that are ingested by consumers, the Company may be subject to various product liability claims. Although we have not had any claims to date, it is possible that future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows. The Company currently maintains products liability insurance of $5 million per-occurrence and a $10 million annual aggregate coverage. At December 31, 2018 and 2017 , the Company had not recorded any accruals for product liability claims.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 14 – RELATED PARTY TRANSACTIONS The following is a description of the transactions we have engaged in with our directors, director nominees and officers and beneficial owners of more than five percent of our voting securities and their affiliates: In October 2016, the Company received a purchase order from RENS Agriculture, an affiliate of Rens Technology Inc., and Ren Ren, one of the Company’s directors, to purchase $116 of our product. The Company received a 50% deposit in November 2016 in order to manufacture the product. The goods were shipped in January 2017 and received in China in March 2017. The Company has not received payment for the order to date. As a result of the ongoing litigation (see Note 15), the Company recorded an allowance for bad debt of $59 for the year ended December 30, 2017 related to the receivable due from RENS Agriculture and the allowance was reversed as of December 31, 2018 when the receivable was reversed. On August 30, 2018, the Company issued an unsecured promissory note (the “Note”) in the principal amount of $750 in favor of Joseph Mannello, the Company’s chief executive officer (the “Lender”). Pursuant to the Note, on August 30, 2018, the Lender advanced $500 of funds to the Company. On September 26, 2018, the Lender advanced an additional $250 of funds to the Company. On November 13, 2018, the Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. On December 29, 2018, the Lender advanced an additional $250 of funds to the Company. As of December 31, 2018, the Company recorded $1,000 as a liability on the consolidated balance sheets. The Note accrues interest at a rate of 5% per annum and all payments of principal, interest and other amounts under the Note are payable on August 31, 2019 or earlier under certain circumstances. The Company may prepay, in whole or in part, at any time, the principal, interest and other amounts owing under the Note, without penalty. The proceeds of the Note will be used by the Company for general working capital purposes. As of December 31, 2018 the Company accrued $15 of interest expense on the Note. In January 2019, prior to receipt of the proceeds from the sale of its net operating losses, the Company received a Board approved advance from its chief executive officer of $250 that was repaid on January 29, 2019. Subsequent to year end, on March 20, 2019, the Company entered into a securities purchase agreement with a group of accredited investors, including two members of the Company’s board of directors, in a private placement for aggregate gross proceeds of $2.1 million, which includes the conversion of $250 of the principal amount of a $1.0 million promissory note previously issued by the Company to its chief executive officer.

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2018
Legal Proceedings [Abstract]
LEGAL PROCEEDINGS	NOTE 15 – LEGAL PROCEEDINGS On January 6, 2017, in connection with the financing contemplated by a securities purchase agreement with RENS Technology Inc. (the “Purchaser”), we commenced an action in the Supreme Court of New York, County of New York (the “Court”), against the Purchaser, RENS Agriculture, the parent company of the Purchaser, and Ren Ren, a principal in both entities and one of our directors, arising from the Purchaser’s breach of the agreement under which the Purchaser agreed to invest an aggregate of $20.25 million in our company in exchange for an aggregate of 3,537,037 shares of our common stock and warrants to purchase an aggregate of 884,259 shares of common stock. On April 11, 2017, the Court noted that we had demonstrated a likelihood of success on the merits of the breach of contract claim. Thereafter, a hearing was scheduled on the application by the Purchaser to dismiss the complaint and various pre-trial discovery applications by both parties. In August 2017, before the hearing occurred, the Company amended its complaint repeating most of the initial claims but adding several additional claims against RENS Agriculture, Mr. Ren and two additional Chinese defendants, including a claim against RENS Agriculture for breaching the exclusive distribution agreement, as well as claims against all defendants for theft and misappropriation of our confidential proprietary information and trade secrets, breach of fiduciary duty and duty of loyalty, misappropriation of corporate opportunity, unfair competition and a number of other torts. We are seeking damages and injunctive relief. The Purchaser has filed a motion to dismiss the amended complaint, which is still pending and scheduled for oral argument in the second quarter of 2019. On August 16, 2017, the Purchaser commenced an action in the District Court of Clark County in the State of Nevada against us and Joseph Mannello, our then interim Chief Executive Officer, alleging that Mr. Mannello had breached his fiduciary duties and was grossly negligent in managing our company. The action seeks monetary damages and injunctive relief from Mr. Mannello as well as the appointment of a receiver over us. Subsequently, the Purchaser submitted a petition to appoint a receiver and we and Mr. Mannello submitted a motion to dismiss the action, both of which are currently pending and are due to be heard in the second quarter of 2019. An application on consent to adjourn the hearing date on the receiver application and motion to dismiss is pending. The parties are currently in settlement discussions regarding the foregoing matters. The outcome of the aforementioned matters cannot be determined as of the date of these consolidated financial statements.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 – SUBSEQUENT EVENTS At-the-Market Offering Subsequent to year end on January 15, 2019, the Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019 the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $145 in an at-the-market offering. As of the filing date of this Report, a total of 882,649 shares were sold under at-the market offerings for aggregate gross proceeds of $1,755. In November 2018 the Company received approval to sell a portion of its state net operating losses through the State of New Jersey Economic Development Authority (NJEDA) Technology Business Tax Certificate Program. In January 2019 the Company received net proceeds of $1,124 for the sale of its net operating losses. In January 2019, prior to receipt of the sale proceeds, the Company received a Board approved advance from its chief executive officer of $250 that was repaid on January 29, 2019. Subsequent to year end, on March 20, 2019, the Company entered into a securities purchase agreement with a group of accredited investors, including two members of the Company’s board of directors, providing for the issuance and sale by the Company of 1,438,356 shares of common stock in a private placement at a purchase price of $1.46 per share, for aggregate gross proceeds of $2.1 million, which includes the conversion of $250 of the principal amount of a $1.0 million promissory note previously issued by the Company to its chief executive officer. The offering closed on March 27, 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance to U.S. GAAP and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial information presented herein reflects all normal adjustments that are, in the opinion of management, necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The Company is responsible for the consolidated financial statements included in this report.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of MYOS RENS Technology Inc. and its wholly-owned subsidiary, Atlas Acquisition Corp. All material intercompany balances and transactions have been eliminated in consolidation.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications did not have an impact on the reported results of operations.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, equity and the disclosures of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates. Significant items subject to such estimates include but are not limited to the valuation of stock-based awards, measurement of allowances for doubtful accounts and inventory reserves, the selection of asset useful lives, fair value estimations used to test long-lived assets, including intangibles, impairments and provisions necessary for assets and liabilities. The Company has recorded minimal sales to its distributors during the past eighteen consecutive quarters. Management’s estimates, including evaluation of impairment of long-lived assets and inventory reserves are based in part on forecasted future results. A variety of factors could cause actual results to differ from forecasted results and these differences could have a significant effect on asset carrying amounts.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three months or less and money market accounts to be cash equivalents. At December 31, 2018 and 2017, the Company had no cash equivalents. The Company maintains its bank accounts with high credit quality financial institutions and has never experienced any losses related to these bank accounts. The Company minimizes its credit risk associated with cash by periodically evaluating the credit quality of its financial institutions. As part of our ongoing liquidity assessments management evaluates our cash, cash equivalents. The amount of funds held in bank can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities so the Company may at times have exposure to cash in excess of FDIC insured limits.
Concentrations of Credit Risk, Significant Customers and Significant Supplier	Concentrations of Credit Risk, Significant Customers and Significant Supplier Management regularly reviews accounts receivable, and if necessary, establishes an allowance for doubtful accounts that reflects management’s best estimate of amounts that may not be collectible based on historical collection experience and specific customer information. Accounts receivable is non-interest bearing. Credit is issued to customers without collateral. If an account becomes delinquent management will review if a write off is appropriate. Expense recognized as a result of an allowance for doubtful accounts is classified under selling, general and administrative expenses in the consolidated statements of operations. As part of our ongoing liquidity assessments, management evaluates our cash and cash equivalents. The amount of funds held in the bank can fluctuate due to the timing of receipts and payments during the ordinary course of business and other reasons, such as business-development activities. The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the FDIC. Management monitors the soundness of these institutions to minimize the Company’s risk. As a result, the Company may have exposure to cash in excess of FDIC insured limits. For the year ended December 31, 2018, the Company had a concentration of revenue with one major customer accounting for 21% of total revenue. For the year ended December 31, 2017, the Company had a concentration of revenue with one major customer accounting for 38 percent of total revenue. A loss of a major customer could have a material adverse effect on future operating results. As of December 31, 2018, accounts receivable from this major customer amounted to approximately 99% of total accounts receivable. For the year ended December 31, 2017 there were no receivables from a major customer. Failure to collect these receivables could have a material adverse effect on our future operating results. For the years ended December 31, 2018 and 2017, the Company purchased its raw material from one third party supplier. The Company believes alternative suppliers could be located in the event of a disruption in availability of goods from this supplier. The Company had the following concentrations of accounts receivable with customers: December 31, 2018 2017 Direct-to-consumer $ 78 $ 4 Related party sale - 59 Subtotal 78 63 Allowance for doubtful accounts - (59 ) Accounts receivable, net $ 78 $ 4 The Company had the following concentrations of revenues with customers: December 31, 2018 2017 Cenegenics - 38 % Vitamin Shoppe 21 % -
Inventories, net	Inventories, net Inventories are valued at the lower of cost or net realizable value, with cost determined on a first in, first-out basis. Each quarter the Company evaluates the need for a change in the inventory reserve based on sales and expiration dates of products. As of December 31, 2018, all expired product had been fully reserved and removed from inventory.
Fixed Assets	Fixed Assets Fixed assets are stated at cost and depreciated to their estimated residual value over their estimated useful lives of 3 to 7 years. Leasehold improvements are amortized over the lesser of the asset’s useful life or the contractual remaining lease term including expected renewals. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are reversed from the accounts and the resulting gains or losses are included in the Consolidated Statements of Operations. Repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method for all fixed assets. We review our fixed assets for impairment when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. We use an estimate of future undiscounted net cash flows of the related assets or groups of assets over their remaining lives in measuring whether the assets are recoverable. If the assets are determined to be unrecoverable, an impairment loss is calculated by determining the difference between the carrying values and the estimated fair value. We did not consider any of our fixed assets to be impaired during the years ended December 31, 2018 and 2017.
Deferred Offering Costs	Deferred Offering Costs The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering not be completed, deferred offering costs are charged to operations during the period in accordance with SEC guidance. Since the February 21, 2017 sales agreement expired by June 30, 2018, the remaining deferred offering costs of $96 on the Company’s consolidated balance sheets were recognized and recorded within the Company’s consolidated statements of operations as general and administrative expenses for the year ended December 31, 2018. On July 24, 2018, the Company entered into a new sales agreement, incurring $108 of deferred offering costs as of December 31, 2018 which was recorded as a long term other asset on the accompanying consolidated balance sheet.
Intangible Assets	Intangible Assets The Company’s intangible assets consist primarily of intellectual property pertaining to Fortetropin ® In July 2014, the Company acquired the United States patent application for the manufacture of Fortetropin ® In March 2017, the Company launched a new product line Qurr® and a related website qurr.com. The Company capitalized $380 of the costs to build the website in accordance with U.S. GAAP and initially amortized this asset over 60 month’s useful life to March 2022. As of December 31, 2018 the company accelerated the amortization of this asset to December 31, 2019 to mirror the expiration date of the remaining Qurr® in its inventory. Intangible assets also includes patent costs associated with applying for a patent and being issued a patent. Costs to defend a patent and costs to invalidate a competitor’s patent or patent application are expensed as incurred. Upon issuance of the patent, capitalized patent costs are reclassified from intangibles with indefinite lives to intangibles with finite lives and amortized on a straight-line basis over the shorter of the estimated economic life or the initial term of the patent, generally 20 years. Intangible assets at December 31, 2018 and December 31, 2017 consisted of the following: December 31, December 31, 2018 2017 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization - intellectual property (994 ) (784 ) Less: accumulated amortization - website (242 ) (57 ) Total intangibles with finite lives 1,245 1,640 Intangibles with indefinite lives - - Total intangible assets, net $ 1,245 $ 1,640 Amortization expense related to intangible assets for the years ended December 31, 2018 and 2017 was $395 and $267. Impairment testing of intangible assets subject to amortization involves comparing the carrying amount of the asset to the forecasted, undiscounted future cash flows whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. In the event the carrying value of the asset exceeds the undiscounted future cash flows, the carrying value is considered not recoverable and an impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. The computed impairment loss is recognized in the period that the impairment occurs. Assets which are not impaired may require an adjustment to the remaining useful lives for which to amortize the asset. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows, selection of the appropriate discount rate to measure the risk inherent in future cash flow streams, assessment of an asset’s life cycle, competitive trends impacting the asset as well as other factors. Changes in these underlying assumptions could significantly impact the asset’s estimated fair value. Based on eighteen consecutive quarters of minimal revenues combined with changes in the sales channels through which the Company sells its products and an inability to predict future orders, if any, we tested the intellectual property for impairment in the fourth quarter of 2018 and determined that the asset value was recoverable and therefore no impairment was recognized. We did not have any impairment losses recorded during the years ended December 31, 2018 and 2017, respectively. Assuming no additions, disposals or adjustments are made to the carrying values and/or useful lives of the intangible assets, annual amortization expense for intangible assets is estimated to be as follows: (In thousand $) Years Ended December 31, Amount 2019 $ 345 2020 200 2021 200 2022 200 2023 200 2024 100 Total $ 1,245
Fair Value of Long-Lived Assets	Fair Value of Long-Lived Assets We test long-lived assets, including fixed assets and intangibles with finite lives, for recoverability when events or changes in circumstances indicate that the net carrying amount is greater than its fair value. Assets are grouped and evaluated at the lowest level for their identifiable cash flows that are largely independent of the cash flows of other groups of assets. We consider historical performance and future estimated results in our evaluation of potential impairment and then compare the carrying amount of the asset to the future estimated cash flows expected to result from the use of the asset. If the carrying amount of the asset exceeds estimated expected undiscounted future cash flows, we measure the amount of impairment by comparing the carrying amount of the asset to its fair value. The estimation of fair value is generally measured by discounting expected future cash flows at the rate we utilize to evaluate potential investments. We estimate fair value based on the information available in making the necessary estimates, judgments and projections.
Revenue	Revenue Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 (“ASU 2014-09”), as amended, using the modified retrospective method. ASU 2014-09, which is codified in the FASB Accounting Standards Codification as Topic 606, Revenue from Contracts with Customers, The adoption of ASU 2014-09 did not impact the Company’s timing or amounts of revenue recognition. As such, the Company recorded no transition adjustment as of January 1, 2018. However, the additional required qualitative and quantitative disclosures to Topic 606 are provided below. Revenue Recognition Net revenues include products and shipping and handling charges, net of estimates for incentives and other sales allowances or discounts. Our product sales generally do not provide for rights of return. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at the point in time the customer obtains control of the products. We consider charges associated with shipping and handling activities as costs to fulfill our performance obligations. Using probability assessments, we estimate sales incentives expected to be paid over the term of the contract. The majority of our contracts have a single performance obligation and are short term in nature. Sales taxes that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Disaggregation of Revenue Our net revenues by product type are presented below for the year ended December 31, 2018 and 2017. Twelve-month Period Product Type December 31, December 31, Qurr® (1) $ 175 $ 164 Yolked® (2) 117 - Myos Canine Muscle Formula® (3) 44 - Physician Muscle Health Formula (4) 24 24 Cenegenics (5) - 200 Egg Yolk Powder (6) - 116 Rē Muscle Health (6) - 22 Total Net Revenues $ 360 $ 526 (1) Qurr® product was launched in March 2017 (2) Yolked® product was launched in March 2018 (3) Myos Canine Muscle Formula® was launched in June 2018 (4) Physician’s Muscle Health Formula was launched in May 2016 (5) Cenegenics is a Fortetropin ® (6) Egg Yolk Powder and Rē Muscle Health products were no longer available after 2017
Advertising	Advertising The Company charges the costs of advertising to sales and marketing expenses as incurred. Advertising and marketing costs were $308 and $267 for the years ended December 31, 2018 and 2017, respectively. For the year ended December 31, 2018, advertising costs consisted primarily of marketing costs for our new products Yolked® and Myos Canine Muscle Formula®. For the year ended December 31, 2017, advertising costs consisted primarily of marketing costs for our Qurr® line of products.
Shipping and Handling Costs	Shipping and Handling Costs The Company records costs for the shipping and handling of products to our customers in cost of sales. These expenses were $48 and $37 for the years ended December 31, 2018 and 2017, respectively.
Research and Development	Research and Development Research and development expenses consist primarily of the cost of manufacturing our product for clinical study, the cost of conducting clinical studies and the cost of conducting preclinical and research activities. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are initially capitalized and are then recognized as an expense as the related goods are consumed or the services are performed. During the years ended December 31, 2018 and 2017, the Company incurred research and development expenses of $417 and $240 respectively. These included payments to DIL for research of $150 and $210 for the years ended December 31, 2018 and 2017.
Share-based Compensation	Share-based Compensation Share-based payments are measured at their estimated fair value on the date of grant. Share-based awards to non-employees are re-measured at fair value each financial reporting date until performance is completed. Share-based compensation expense recognized during a period is based on the estimated number of awards that are ultimately expected to vest. For stock options and restricted stock that do not vest immediately but which contain only a service vesting feature, we recognize compensation cost on the unvested shares and options on a straight-line basis over the remaining vesting period. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options and the market price of our common stock on the date of grant for the fair value of restricted stock issued. Our determination of the fair value of stock-based awards is affected by our stock price as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and certain other market variables such as the risk-free interest rate.
Segment Information	Segment Information Accounting Standards Codification (“ASC”) 280, Disclosures about Segments of an Enterprise and Related Information
Fair Value Measurement	Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby observable and unobservable inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchy levels of inputs to measure fair value: Level 1 Inputs that utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 Inputs that utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Level 3: Inputs that utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. At December 31, 2018 and 2017 , the Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. Due to their short-term nature, the carrying amounts of the Company’s financial instruments approximated their fair values.
Basic and Diluted Loss Per Share	Basic and Diluted Loss per Share Basic net loss per share is computed by dividing net loss available to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potential dilutive securities outstanding had been issued. The Company uses the “treasury stock” method to determine the dilutive effect of common stock equivalents such as options, warrants and restricted stock. For the years ended December 31, 2018 and 2017, the Company incurred a net loss. Accordingly, the Company’s common stock equivalents were anti-dilutive and excluded from the diluted net loss per share computation. The aggregate number of potentially dilutive common stock equivalents outstanding at December 31, 2018 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,083,082, which includes warrants to purchase an aggregate 821,202 shares of common stock, options to purchase an aggregate of 261,880 shares of common stock and rights under the Rights Agreement. The aggregate number of potentially dilutive common stock equivalents outstanding at December 31, 2017 excluded from the diluted net loss per share computation because their inclusion would be anti-dilutive were 1,067,332, which includes warrants to purchase an aggregate 821,202 shares of common stock, options to purchase an aggregate of 244,880 shares of common stock, and unvested restricted stock awards of 1,250 shares of common stock.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method in accordance with ASC 740, Accounting for Income Taxes The Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017. The Tax Act contains several key provisions including, among other things, reducing the U.S. federal corporate tax rate from thirty-five percent to twenty-one percent. Changes in tax law are accounted for in the period of enactment. In addition, Federal net operating losses (“NOL”) generated during future periods will be carried forward indefinitely, but will be subject to an eighty percent utilization against taxable income. The carryback provision has been revoked for NOL after January 1, 2018. Interest costs and penalties related to income taxes are classified as interest expense and operating expenses, respectively, in the Company’s financial statements. For the years ended December 31, 2018 and 2017, the Company did not recognize any interest or penalty expense related to income taxes. The Company files income tax returns in the U.S. federal jurisdiction and states in which it does business. The Company continues to evaluate the impact of the Tax Act and analyze additional guidance.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Product Information [Line Items]
Schedule of intangible assets	December 31, December 31, 2018 2017 Intangibles with finite lives: Intellectual property $ 2,101 $ 2,101 Website - qurr.com 380 380 Less: accumulated amortization - intellectual property (994 ) (784 ) Less: accumulated amortization - website (242 ) (57 ) Total intangibles with finite lives 1,245 1,640 Intangibles with indefinite lives - - Total intangible assets, net $ 1,245 $ 1,640
Schedule of intangible assets is estimated useful lives	(In thousand $) Years Ended December 31, Amount 2019 $ 345 2020 200 2021 200 2022 200 2023 200 2024 100 Total $ 1,245
Schedule of disaggregation of revenue	Twelve-month Period Product Type December 31, December 31, Qurr® (1) $ 175 $ 164 Yolked® (2) 117 - Myos Canine Muscle Formula® (3) 44 - Physician Muscle Health Formula (4) 24 24 Cenegenics (5) - 200 Egg Yolk Powder (6) - 116 Rē Muscle Health (6) - 22 Total Net Revenues $ 360 $ 526 (1) Qurr® product was launched in March 2017 (2) Yolked® product was launched in March 2018 (3) Myos Canine Muscle Formula® was launched in June 2018 (4) Physician’s Muscle Health Formula was launched in May 2016 (5) Cenegenics is a Fortetropin ® (6) Egg Yolk Powder and Rē Muscle Health products were no longer available after 2017
Accounts Receivable [Member]
Product Information [Line Items]
Schedule of concentrations of net accounts receivable with customers	December 31, 2018 2017 Direct-to-consumer $ 78 $ 4 Related party sale - 59 Subtotal 78 63 Allowance for doubtful accounts - (59 ) Accounts receivable, net $ 78 $ 4
Sales Revenue, Net [Member]
Product Information [Line Items]
Schedule of concentrations of net accounts receivable with customers	December 31, 2018 2017 Cenegenics - 38 % Vitamin Shoppe 21 % -

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Inventories, Net [Abstract]
Schedule of inventory	(In thousands $) December 31, December 31, Raw materials $ 1,769 $ 2,223 Work in process 37 64 Finished goods 135 203 1,941 2,490 Less: inventory reserves (265 ) (711 ) Inventories, net $ 1,676 $ 1,779

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Fixed Assets [Abstract]
Schedule of fixed assets	(In thousands $) December 31, December 31, Furniture, fixtures and equipment $ 116 $ 116 Computers and software 68 68 Leasehold improvements 239 239 Other 7 7 Total fixed assets 430 430 Less: accumulated depreciation and amortization (281 ) (246 ) Net book value of fixed assets $ 149 $ 184

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Prepaid Expenses [Abstract]
Schedule of prepaid expenses	(In thousands $) December 31, December 31, Prepaid insurance $ - $ 88 Prepaid consulting and other 10 25 Total prepaid expenses $ 10 $ 113

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of accrued expenses and other current liabilities	(In thousands $) December 31, December 31, Professional fees $ 85 $ 151 Accrued board compensation 181 Research and development 91 - Insurance premium financing - 66 Deferred rent 10 19 Other accrued expenses 16 19 Total accrued expenses $ 383 $ 255

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity [Abstract]
Schedule of periodical gross proceeds from private placements	Gross Date Shares Proceeds April 29, 2018 806,452 (1) $ 1,000 April 4 – April 23, 2018 131,225 (2) 176 January 19, 2018 140,295 (3) 296 October 31, 2017 500,000 (4) 1,072 February 8, 2017 500,000 (5) 2,125 Total 2,077,972 $ 4,669 (1) Shares issued pursuant to a private placement with accredited investors for $1.24 per share. (2) Shares of common stock sold for between $1.25 and $1.38 per share in an at-the-market offering. (3) Shares of common stock sold for $2.111 per share in an at-the-market offering. (4) Shares of common stock sold for $2.144 per share in an at-the-market offering. (5) Shares issued pursuant to a registered direct offering with an institutional investor for $4.25 per share.

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Warrants [Abstract]
Schedule of outstanding and exercisable warrants issued to private placement	Shares Number of Underlying Shares Shares Warrants Underlying Underlying Exchanged, Warrants Warrants Exercised Outstanding Expiration Originally or and Exercise Term Description Grant Date Granted or Expired Exercisable Price in years Series B (1) January 27, 2014 157,846 - 157,846 $ 45.00 0.07 Series C (2) November 19, 2014 145,399 (142,957 ) 2,442 $ 12.00 1.38 Repricing Series C (2) November 19, 2014 142,957 142,957 $ 9.00 1.38 Repricing Series E (2) November 19, 2014 142,957 142,957 $ 9.00 3.38 Rens (3) March 3, 2016 375,000 - 375,000 $ 7.00 1.06 678,245 142,957 821,202 (1) Issued in connection with the January 27, 2014 private placement transaction. (2) Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015. (3) Shares issued pursuant to the closing of the first tranche of the financing with RENS Technology Inc.

Stock Compensation (Tables)

Stock Compensation (Tables) - Options [Member]	12 Months Ended
	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock option activity	Weighted Weighted Average Shares Average Remaining Under Exercise Contractual Options Price Term (Years) Balance at December 31, 2016 300,340 $ 15.09 6.71 Options granted 300,000 4.00 Options forfeited (38,600 ) 7.15 Balance at December 31, 2017 561,740 $ 7.32 5.61 Options granted 57,000 $ 4.00 Options forfeited (20,000 ) 4.00 Balance at December 31, 2018 598,740 $ 6.76 5.65
Schedule of assumptions used to value stock options granted using a Black-Scholes model	2018 2017 Risk-free interest rate 2.38 % 2.19 % Expected volatility 100 % 100 % Expected forfeiture rate 0 % 0 % Expected term (years) 6.0 6.0 Expected dividend yield 0 % 0 %
Schedule of options outstanding and exercisable	Options Outstanding Options Exercisable Weighted Average Weighted Average Exercise Options Remaining Exercise Options Remaining Price Outstanding Contractual Life Price Exercisable Contractual Life $ 4.00 337,000 9.00 $ 4.00 17,000 9.00 $ 8.60 16,000 5.19 $ 8.60 16,000 5.19 $ 10.00 40 3.89 $ 10.00 40 3.89 $ 12.10 30,000 5.35 $ 12.10 30,000 5.35 $ 12.50 81,700 5.42 $ 12.50 67,278 5.42 $ 13.45 2,000 5.47 $ 13.45 1,000 5.47 $ 13.50 12,000 5.49 $ 13.50 10,562 5.49 $ 17.50 100,000 4.11 $ 17.50 100,000 4.11 $ 32.00 15,000 2.54 $ 32.00 15,000 2.54 $ 34.50 5,000 2.57 $ 34.50 5,000 2.57 598,740 261,880
Schedule of restricted stock awards activity	Weighted Average Grant Date Shares Share Price Restricted stock awards unvested at December 31, 2016 53,857 $ 2.74 Vested (46,607 ) 5.17 Forfeited (6,000 ) 1.75 Restricted stock awards unvested at December 31, 2017 1,250 1.02 Granted 63,137 1.36 Vested (64,387 ) 1.30 Restricted stock awards unvested at December 31, 2018 - $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Taxes [Abstract]
Summary of income tax expense	December 31, December 31, (In thousand $) 2018 2017 Current provision $ (1,124 ) $ - Deferred provision - - Total tax provision (benefit) $ (1,124 ) $ -
Schedule of components of deferred tax assets and liabilities	December 31, December 31, (In thousand $) 2018 2017 Federal net operating losses $ 5,669 $ 5,029 State net operating losses 31 886 Stock options 646 701 Federal tax credit 190 190 Amortization 198 283 Depreciation 20 (3 ) Accrued expenses 4 - Contributions 10 14 Other 62 194 Total gross deferred tax assets/(liabilities) 6,830 7,294 Less valuation allowance (6,830 ) (7,294 ) Net deferred tax assets/(liabilities) $ - $ -
Schedule of statutory federal income tax rate and the effective rate reconciliation	December 31, December 31, (In thousand $) 2018 2017 Federal statutory tax benefit $ (676 ) $ (852 ) Sale of NJ NOL credits (1,124 ) - Permanent differences 30 35 Research & development - (42 ) State taxes 2 1 True up 54 - Valuation allowance 591 (2,307 ) Effective tax rate dollars $ (1,123 ) $ (3,165 ) Effective tax rate percentage 34.74 % 77.98 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Operating Leased Assets [Line Items]
Schedule of future minimum lease payments under the non-cancellable operating lease	(In thousand $) Years Ended December 31, Amount 2019 $ 72 Total $ 72
Schedule of supply agreement	Years Ended December 31, Amount 2019 $ 91 2020 102 Total $ 193

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Liquidity (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 20, 2019	Jan. 15, 2019	Nov. 13, 2018	Apr. 25, 2018	Feb. 21, 2017	Feb. 03, 2017	Dec. 17, 2015	Mar. 19, 2019	Aug. 30, 2018	Jul. 24, 2018	Apr. 30, 2018	Jan. 19, 2018	Oct. 26, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 27, 2018	Nov. 19, 2018	Sep. 26, 2018	Apr. 29, 2018	Apr. 23, 2018	Apr. 04, 2018	Feb. 08, 2017	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gross proceeds of common stock value						$ 2,125								$ 1,755
Offering costs value						$ 199								1,444	$ 2,944
Net loss														(3,223)	(4,058)
Cash														15	923								$ 1,866
Current assets														2,903	2,819
Current liabilities														1,634	431
Net cash used in operating activities														(3,250)	(3,783)
Aggregate gross proceeds											$ 176	$ 296	$ 1,070
Shares of common stock											131,225	140,295	500,000
Sale of stock price per share						$ 4.25						$ 2.111	$ 2.144						$ 1.24	$ 1.38	$ 1.25	$ 4.25
Gross proceeds from sale of stock														$ 1,609
Sale of stock, shares						500,000								882,649
Common stock, par value														$ 0.001	$ 0.001
Deferred offering costs					$ 96									$ 108	$ 102
Common stock offer shares														1,450	2,944
Remaining deferred offering costs														96
Lender advanced additional of funds									$ 500							$ 250	$ 250	$ 250
Note payable, description			The Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000.
Accrued of interest expense														2
Accrued interest expense														15
Private Placement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gross proceeds of common stock value				$ 1,000
Sale of stock price per share				$ 1.24
Sale of stock, shares				806,452
Net proceeds from private sale of stock				$ 978
H.C. Wainwright [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Offering costs value					6,000					$ 1,600
Deferred offering costs					$ 125					$ 108
Cenegenics [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales															200
Re Muscle Health [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales															22
Physician Muscle Health Formula [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales														24	24
Qurr [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales														175	$ 164
Yolked [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales														117
Myos Canine Muscle Formula [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Sales														$ 44
Joseph Mannello [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Unsecured promissory note principal amount									$ 750
Accrues interest percentage									5.00%
Subsequent Event [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Gross proceeds of common stock value	$ 2,100	$ 65						$ 145
Shares of common stock		32,489
Sale of stock price per share	$ 1.46	$ 2						$ 1.85
Gross proceeds from sale of stock		$ 65
Sale of stock, shares	1,438,356	32,489						78,640
Note payable, description		The Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019 the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $145 in an at-the-market offering. As of the filing date of this Report, a total of 882,649 shares were sold under at-the market offerings for aggregate gross proceeds of $1,755.
Purchase Agreement [Member] | RENS Technology Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate common shares							3,537,037
Payments of financing							$ 20,500
Common stock, par value							$ 0.001
Purchase Agreement [Member] | First tranche [Member] | RENS Technology Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Purchaser acquired, shares														1,500,000
Warrants acquired														375,000
Purchaser acquired, value														$ 5,250
Securities close date, description														The first tranche which closed on March 3, 2016.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Concentration Risk [Line Items]
Subtotal	$ 78	$ 63
Allowance for doubtful accounts		(59)
Accounts receivable, net	78	4
Direct-to-consumer [Member]
Concentration Risk [Line Items]
Subtotal	78	4
Related Party Sale [Member]
Concentration Risk [Line Items]
Subtotal		$ 59

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cenegenics [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		38.00%
Vitamin Shoppe [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	21.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Intangibles with finite lives:
Intangibles with finite lives	$ 1,245	$ 1,640
Less: accumulated amortization
Total intangible assets, net	1,245	1,640
Intellectual property [Member]
Intangibles with finite lives:
Intangibles with finite lives	2,101	2,101
Less: accumulated amortization	(994)	(784)
Website - qurr.com [Member]
Intangibles with finite lives:
Intangibles with finite lives	380	380
Less: accumulated amortization	$ (242)	$ (57)

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Summary of Significant Accounting Policies [Abstract]
2019	$ 345
2020	200
2021	200
2022	200
2023	200
2024	100
Total	$ 1,245	$ 1,640

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details 4) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Total Net Revenues		$ 360	$ 526
Qurr [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[1]	175	164
Yolked [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[2]	117
Myos Canine Muscle Formula [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[3]	44
Physician Muscle Health Formula [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[4]	24	24
Cenegenics [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[5]		200
Related Party Sale [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[6]		116
Re Muscle Health [Member]
Disaggregation of Revenue [Line Items]
Total Net Revenues	[6]		$ 22
[1]	Qurr® product was launched in March 2017
[2]	Yolked® product was launched in March 2018
[3]	Myos Canine Muscle Formula® was launched in June 2018
[4]	Physician's Muscle Health Formula was launched in May 2016
[5]	Cenegenics is a Fortetropin® based product we produce as a private label as it is ordered.
[6]	Egg Yolk Powder and Re Muscle Health products were no longer available after 2017

Summary of Significant Accoun_9

Summary of Significant Accounting Policies (Details Textual) $ in Thousands	1 Months Ended			12 Months Ended
	Mar. 31, 2017USD ($)	Jul. 31, 2014USD ($)	Apr. 30, 2014	Dec. 31, 2018USD ($)SegmentsCustomersshares	Dec. 31, 2017USD ($)shares	Feb. 21, 2017USD ($)	Dec. 31, 2011USD ($)
Summary of Significant Accounting Policies (Textual)
Allowance for doubtful accounts					$ 59
Provision for Doubtful Accounts					59
Deferred offering costs				$ 108	102	$ 96
Estimated useful lives of fixed assets				3 to 7 years
Estimated useful life of intangible assets		10 years
Intangible asset acquired		$ 101
Discount rate		10.00%
Capitalized costs	$ 380
Amortized period	60 months
Advertising and promotional costs				$ 308	267
Research and development cost				$ 417	$ 240
Potentially dilutive common stock equivalents outstanding | shares				1,083,082	1,067,332
Sale of product				$ 360
Amortization				$ 395	$ 267
Number of segment | Segments				1
Accounts Receivable [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage				99.00%
Number of customer | Customers				1
Total Revenue [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage				21.00%	38.00%
General and administrative operating expenses [Member]
Summary of Significant Accounting Policies (Textual)
Deferred offering costs				$ 96
Research and development expense [Member]
Summary of Significant Accounting Policies (Textual)
Research and development cost				150	$ 210
Shipping and Handling [Member]
Summary of Significant Accounting Policies (Textual)
Sale of product				$ 48	$ 37
Warrant [Member]
Summary of Significant Accounting Policies (Textual)
Potentially dilutive common stock equivalents outstanding | shares				821,202	821,202
Options [Member]
Summary of Significant Accounting Policies (Textual)
Potentially dilutive common stock equivalents outstanding | shares				261,880	244,880
Unvested restricted stock awards [Member]
Summary of Significant Accounting Policies (Textual)
Potentially dilutive common stock equivalents outstanding | shares				1,250
Patents [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful life of intangible assets		20 years
Intellectual property [Member]
Summary of Significant Accounting Policies (Textual)
Intellectual property asset, fair value							$ 2,000
Estimated useful life of intangible assets			10 years

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Summary of Inventory
Raw materials	$ 1,769	$ 2,223
Work in process	37	64
Finished goods	135	203
Inventories, gross	1,941	2,490
Less: inventory reserves	(265)	(711)
Inventories, net	$ 1,676	$ 1,779

Fixed Assets (Details)

Fixed Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Summary of fixed assets
Total fixed assets	$ 430	$ 430
Less: accumulated depreciation and amortization	(281)	(246)
Net book value of fixed assets	149	184
Furniture, fixtures and equipment [Member]
Summary of fixed assets
Total fixed assets	116	116
Computers and software [Member]
Summary of fixed assets
Total fixed assets	68	68
Leasehold improvements [Member]
Summary of fixed assets
Total fixed assets	239	239
Other [Member]
Summary of fixed assets
Total fixed assets	$ 7	$ 7

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fixed Assets (Textual)
Depreciation expense	$ 35	$ 51

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Summary of prepaid expenses and other current assets
Prepaid insurance		$ 88
Prepaid consulting and other	10	25
Total prepaid expenses	$ 10	$ 113

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued Expenses and Other Current Liabilities [Abstract]
Professional fees	$ 85	$ 151
Accrued board compensation	181
Research and development	91
Insurance premium financing		66
Deferred rent	10	19
Other accrued expenses	16	19
Total accrued expenses	$ 383	$ 255

Related Party Promissory Note_2

Related Party Promissory Note and Accrued Interest (Details) - USD ($) $ in Thousands	Jan. 15, 2019	Nov. 13, 2018	Aug. 30, 2018	Mar. 20, 2019	Dec. 31, 2018	Dec. 27, 2018	Nov. 19, 2018	Sep. 26, 2018
Related Party Promissory Note and Accrued Interest (Textual)
Lender advanced additional of funds			$ 500			$ 250	$ 250	$ 250
Note payable, description		The Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000.
Accrued interest expense					$ 15
Principal amount			750
Joseph Mannello [Member]
Related Party Promissory Note and Accrued Interest (Textual)
Unsecured promissory note principal amount			$ 750
Accrues interest percentage			5.00%
Subsequent Event [Member]
Related Party Promissory Note and Accrued Interest (Textual)
Note payable, description	The Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019 the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $145 in an at-the-market offering. As of the filing date of this Report, a total of 882,649 shares were sold under at-the market offerings for aggregate gross proceeds of $1,755.
Aggregate gross proceeds				$ 2,100
Conversion of promissory note				250
Principal amount				$ 1,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Gross Proceeds, Total		$ 1,450	$ 2,944
Common Stock [Member]
Class of Stock [Line Items]
Shares, Total		2,077,972
Gross Proceeds, Total		$ 4,669
Common Stock [Member] | April 29, 2018 [Member]
Class of Stock [Line Items]
Shares, Total	[1]	806,452
Gross Proceeds, Total		$ 1,000
Common Stock [Member] | April 4 - April 23, 2018 [Member]
Class of Stock [Line Items]
Shares, Total	[2]	131,225
Gross Proceeds, Total		$ 176
Common Stock [Member] | January 19, 2018 [Member]
Class of Stock [Line Items]
Shares, Total	[3]	140,295
Gross Proceeds, Total		$ 296
Common Stock [Member] | October 31, 2017 [Member]
Class of Stock [Line Items]
Shares, Total	[4]	500,000
Gross Proceeds, Total		$ 1,072
Common Stock [Member] | February 8, 2017 [Member]
Class of Stock [Line Items]
Shares, Total	[5]	500,000
Gross Proceeds, Total		$ 2,125
[1]	Shares issued pursuant to a private placement with accredited investors for $1.24 per share.
[2]	Shares of common stock sold for between $1.25 and $1.38 per share in an at-the-market offering.
[3]	Shares of common stock sold for $2.111 per share in an at-the-market offering.
[4]	Shares of common stock sold for $2.144 per share in an at-the-market offering.
[5]	Shares issued pursuant to a registered direct offering with an institutional investor for $4.25 per share.

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Mar. 20, 2019	Jan. 15, 2019	Apr. 25, 2018	Feb. 21, 2017	Feb. 14, 2017	Feb. 03, 2017	Mar. 19, 2019	Jul. 24, 2018	Apr. 30, 2018	Jan. 31, 2018	Jan. 19, 2018	Oct. 26, 2017	Dec. 31, 2018	Dec. 31, 2017	Apr. 29, 2018	Apr. 23, 2018	Apr. 04, 2018	Feb. 08, 2017	Oct. 26, 2016
Stockholders' Equity (Textual)
Proceeds from issuance of private placement and public offering													$ 1,472	$ 3,197
Beneficial ownership, percentage													10.00%
Sale of common stock, shares						500,000							882,649
Sale of purchase price per share						$ 4.25					$ 2.111				$ 1.24	$ 1.38	$ 1.25	$ 4.25	$ 2.144
Gross proceeds of common stock value						$ 2,125							$ 1,755
Offering costs value						$ 199							1,444	2,944
Deferred offering costs				$ 96									108	102
Board compensation										$ 65			$ 235	160
Subsequent Event [Member]
Stockholders' Equity (Textual)
Sale of common stock, shares	1,438,356	32,489					78,640
Sale of purchase price per share	$ 1.46	$ 2					$ 1.85
Gross proceeds of common stock value	$ 2,100	$ 65					$ 145
H.C. Wainwright & Co., LLC [Member]
Stockholders' Equity (Textual)
Offering costs value				6,000				$ 1,600
Deferred offering costs				$ 125				$ 108
Common Stock [Member]
Stockholders' Equity (Textual)
Shares of restricted common stock under its equity incentive plan													55,147
Sale of common stock, shares									131,225		140,295	500,000
Sale of purchase price per share											$ 2.111	$ 2.144
Gross proceeds of common stock value									$ 176		$ 296	$ 1,072
Offering costs value													$ 1	$ 1
Private Placement [Member]
Stockholders' Equity (Textual)
Sale of common stock, shares			806,452
Sale of purchase price per share			$ 1.24
Gross proceeds of common stock value			$ 1,000
Net proceeds from private sale of stock			$ 978
Series A Preferred Stock [Member]
Stockholders' Equity (Textual)
Series A preferred stock purchase right, description					Each Right entitles the registered holder, upon the occurrence of certain events specified in the Rights Agreement, to purchase from the Company one one-thousandth of a share of the Company's Series A Preferred Stock at a price of $7.00, subject to certain adjustments.

Warrants (Details)

Warrants (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Summarizes information about warrants outstanding and exercisable
Number of Shares Underlying Warrants Originally Granted	678,245
Shares Underlying Warrants Exchanged, Exercised or Expired	142,957
Shares Underlying Warrants Outstanding and Exercisable	821,202
Series B January 27, 2014 [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	Jan. 27, 2014	[1]
Number of Shares Underlying Warrants Originally Granted	157,846	[1]
Shares Underlying Warrants Exchanged, Exercised or Expired		[1]
Shares Underlying Warrants Outstanding and Exercisable	157,846	[1]
Exercise price | $ / shares	$ 45	[1]
Expiration Term in years	26 days	[1]
Series C November 19, 2014 [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	Nov. 19, 2014	[2]
Number of Shares Underlying Warrants Originally Granted	145,399	[2]
Shares Underlying Warrants Exchanged, Exercised or Expired	(142,957)	[2]
Shares Underlying Warrants Outstanding and Exercisable	2,442	[2]
Exercise price | $ / shares	$ 12	[2]
Expiration Term in years	1 year 4 months 17 days	[2]
Repricing Series C November 19, 2014 [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	Nov. 19, 2014	[2]
Number of Shares Underlying Warrants Originally Granted		[2]
Shares Underlying Warrants Exchanged, Exercised or Expired	142,957	[2]
Shares Underlying Warrants Outstanding and Exercisable	142,957	[2]
Exercise price | $ / shares	$ 9	[2]
Expiration Term in years	1 year 4 months 17 days	[2]
Repricing Series E November 19, 2014 [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	Nov. 19, 2014	[2]
Number of Shares Underlying Warrants Originally Granted		[2]
Shares Underlying Warrants Exchanged, Exercised or Expired	142,957	[2]
Shares Underlying Warrants Outstanding and Exercisable	142,957	[2]
Exercise price | $ / shares	$ 9	[2]
Expiration Term in years	3 years 4 months 17 days	[2]
Rens March 3, 2016 [Member]
Summarizes information about warrants outstanding and exercisable
Grant Date	Mar. 3, 2016	[3]
Number of Shares Underlying Warrants Originally Granted	375,000	[3]
Shares Underlying Warrants Exchanged, Exercised or Expired		[3]
Shares Underlying Warrants Outstanding and Exercisable	375,000	[3]
Exercise price | $ / shares	$ 7	[3]
Expiration Term in years	1 year 22 days	[3]
[1]	Issued in connection with the January 27, 2014 private placement transaction.
[2]	Issued in connection with the November 19, 2014 registered-direct public offering, and subsequently revised pursuant to Warrant Exercise Agreements entered into on May 18, 2015.
[3]	Shares issued pursuant to the closing of the first tranche of the financing with RENS Technology Inc.

Stock Compensation (Details)

Stock Compensation (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options granted, Shares Under Options	678,245
Ending Balance, Shares Under Exercisable Warrants / Options	598,740
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning Balance, Shares Under Exercisable Warrants / Options	561,740	300,340
Options granted, Shares Under Options	57,000	300,000
Options forfeited, Shares Under Options	(20,000)	(38,600)
Ending Balance, Shares Under Exercisable Warrants / Options	598,740	561,740
Beginning Balance, Weighted Average Exercise Price	$ 7.32	$ 15.09
Options granted, Weighted Average Exercise Price	4	4
Options canceled, Weighted Average Exercise Price	4	7.15
Ending Balance, Weighted Average Exercise Price	$ 6.67	$ 7.32
Options beginning, Weighted Average Remaining Contractual Term (Years)	5 years 7 months 10 days	6 years 8 months 16 days
Options ending, Weighted Average Remaining Contractual Term (Years)	5 years 7 months 24 days	5 years 7 months 10 days

Stock Compensation (Details 1)

Stock Compensation (Details 1) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.38%	2.19%
Expected volatility	100.00%	100.00%
Expected forfeiture rate	0.00%	0.00%
Expected term (years)	6 years	6 years
Expected dividend yield	0.00%	0.00%

Stock Compensation (Details 2)

Stock Compensation (Details 2)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Summary of option outstanding and exercisable
Options outstanding	598,740
Options Exercisable	261,880
$ 4.00 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 4
Options outstanding	337,000
Options, Weighted Average Remaining Contractual Life	9 years
Options Exercisable, exercise price | $ / shares	$ 4
Options Exercisable	17,000
Options Exercisable, Weighted Average Remaining Contractual Life	9 years
$ 8.60 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 8.60
Options outstanding	16,000
Options, Weighted Average Remaining Contractual Life	5 years 2 months 8 days
Options Exercisable, exercise price | $ / shares	$ 8.60
Options Exercisable	16,000
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 2 months 8 days
$ 10.00 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 10
Options outstanding	40
Options, Weighted Average Remaining Contractual Life	3 years 10 months 21 days
Options Exercisable, exercise price | $ / shares	$ 10
Options Exercisable	40
Options Exercisable, Weighted Average Remaining Contractual Life	3 years 10 months 21 days
$ 12.10 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 12.10
Options outstanding	30,000
Options, Weighted Average Remaining Contractual Life	5 years 4 months 6 days
Options Exercisable, exercise price | $ / shares	$ 12.10
Options Exercisable	30,000
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 4 months 6 days
$ 12.50 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 12.50
Options outstanding	81,700
Options, Weighted Average Remaining Contractual Life	5 years 5 months 1 day
Options Exercisable, exercise price | $ / shares	$ 12.50
Options Exercisable	67,278
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 5 months 1 day
$ 13.45 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 13.45
Options outstanding	2,000
Options, Weighted Average Remaining Contractual Life	5 years 5 months 20 days
Options Exercisable, exercise price | $ / shares	$ 13.45
Options Exercisable	1,000
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 5 months 20 days
13.50 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 13.50
Options outstanding	12,000
Options, Weighted Average Remaining Contractual Life	5 years 5 months 27 days
Options Exercisable, exercise price | $ / shares	$ 13.50
Options Exercisable	10,562
Options Exercisable, Weighted Average Remaining Contractual Life	5 years 5 months 27 days
17.50 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 17.50
Options outstanding	100,000
Options, Weighted Average Remaining Contractual Life	4 years 1 month 9 days
Options Exercisable, exercise price | $ / shares	$ 17.50
Options Exercisable	100,000
Options Exercisable, Weighted Average Remaining Contractual Life	4 years 1 month 9 days
32.00 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 32
Options outstanding	15,000
Options, Weighted Average Remaining Contractual Life	2 years 6 months 14 days
Options Exercisable, exercise price | $ / shares	$ 32
Options Exercisable	15,000
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 6 months 14 days
34.50 [Member]
Summary of option outstanding and exercisable
Exercise Price | $ / shares	$ 34.50
Options outstanding	5,000
Options, Weighted Average Remaining Contractual Life	2 years 6 months 25 days
Options Exercisable, exercise price | $ / shares	$ 34.50
Options Exercisable	5,000
Options Exercisable, Weighted Average Remaining Contractual Life	2 years 6 months 25 days

Stock Compensation (Details 3)

Stock Compensation (Details 3) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning Balance, Shares	1,250	53,857
Shares Granted	63,137
Shares Vested	(64,387)	(46,607)
Shares Forfeited		(6,000)
Ending Balance, Shares		1,250
Beginning Balance, Weighted Average Grant Date Share Price	$ 1.02	$ 2.74
Shares Granted, Weighted Average Grant Date Share Price	1.36
Shares Vested, Weighted Average Grant Date Share Price	1.30	5.17
Shares Forfeited, Weighted Average Grant Date Share Price		1.75
Ending Balance, Weighted Average Grant Date Share Price		$ 1.02

Stock Compensation (Details Tex

Stock Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Nov. 30, 2016
Stock Compensation (Textual)
Stock-based compensation expenses	$ 65	$ 235	$ 160
Number of option granted		678,245
Aggregate unrecognized compensation expense of options
Weighted average grant date fair value stock options granted		47,000
Stock Options [Member]
Stock Compensation (Textual)
Number of shares authorized for issuance		850,000
Number of option granted		57,000
Maturity years		6 years	6 years
Risk Free Rate		2.38%	2.19%
Expected Volatility		100.00%	100.00%
Exercisable options had no intrinsic value
2012 Equity Incentive Plan [Member]
Stock Compensation (Textual)
Common stock reserved for issuance		251,260
Stock options exercisable, description		Stock options generally vest and become exercisable with respect to 100% of the common stock.
Vested options, weighted average remaining contractual life		5 years 8 months 12 days
Vested options weighted average exercise price, per share		$ 15.7
Number of option granted		30,000
Number of shares vested		261,880
Number of options unvested		336,860
Exercise price		$ 1.25
2012 Equity Incentive Plan [Member] | Minimum [Member]
Stock Compensation (Textual)
Number of shares authorized for issuance				550,000
Vesting terms range		4 years 6 months
2012 Equity Incentive Plan [Member] | Maximum [Member]
Stock Compensation (Textual)
Number of shares authorized for issuance				850,000
Vesting terms range		9 years

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income tax expense
Current provision	$ (1,124)
Deferred provision
Total tax provision (benefit)	$ (1,124)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Taxes [Abstract]
Federal net operating losses	$ 5,669	$ 5,029
State net operating losses	31	886
Stock options	646	701
Federal tax credit	190	190
Amortization	198	283
Depreciation	20	(3)
Accrued expenses	4
Contributions	10	14
Other	62	194
Total gross deferred tax assets/(liabilities)	6,830	7,294
Less valuation allowance	(6,830)	(7,294)
Net deferred tax assets/(liabilities)

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statutory federal income tax rate and the effective rate reconciliation
Federal statutory tax benefit	$ (676)	$ (852)
Sale of NJ NOL credits	(1,124)
Permanent differences	30	35
Research & development		(42)
State taxes	2	1
True up	54
Valuation allowance	591	(2,307)
Effective tax rate dollars	$ (1,124)
Effective tax rate percentage	34.74%	77.98%

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Taxes (Textual)
U.S. federal income tax rate		21.00%
Federal net operating loss carry-forwards		$ 5,669	$ 5,029
Federal and state net operating loss carry-forwards		31	886
Federal tax credit		$ 190	190
Federal and state income tax examination, description		The federal and state income tax returns of the Company for 2014, 2015, 2016 and 2017 are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.
Federal research and development credits, expiration date		Dec. 31, 2033
Valuation allowances		$ 6,800	7,300
Subsequent Event [Member]
Income Taxes (Textual)
Net proceeds from sale of net operating losses	$ 1,124
Domestic Tax Authority [Member]
Income Taxes (Textual)
Federal net operating loss carry-forwards		$ 26,900	$ 23,700
Federal research and development credits, expiration date		Dec. 31, 2027

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2018USD ($)
Summary of future minimum lease payments under the non-cancellable operating lease
2019	$ 72
Total	$ 72

Commitments and Contingencies_3

Commitments and Contingencies (Details 1) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies [Abstract]
2019	$ 91
2020	102
Total	$ 193

Commitments and Contingencies_4

Commitments and Contingencies (Details Textual) € in Thousands, $ in Thousands	Nov. 18, 2016	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)	Jan. 31, 2017USD ($)	Jan. 31, 2017EUR (€)
Commitments and Contingencies (Textual)
Rent expense		$ 79	$ 68
Collaborative research					€ 194	$ 12	€ 10
Lease expiration date		Dec. 31, 2019
Contribution plan, description		The Company's matching contribution is equal to 100 percent on the first four percent of a participant's compensation which is deferred as an elective deferral. The Company's aggregate matching contributions were $33 and $26 for the years ended December 31, 2018 and 2017, respectively.
Matching contribution, amount		$ 33	$ 26
Renewal term of agreement, description		We have not had any claims to date, it is possible that future product liability claims could have a material adverse effect on our business or financial condition, results of operations or cash flows.
Term of lease		5 years
Product liability insurance, description		The Company currently maintains products liability insurance of $5 million per-occurrence and a $10 million annual aggregate coverage. At December 31, 2018 and 2017, the Company had not recorded any accruals for product liability claims.
Supply Agreement [Member]
Commitments and Contingencies (Textual)
Collaborative research		$ 150
Expiration date of agreement	Dec. 31, 2018
Satisfaction of all prior liabilities and obligations		$ 480		€ 400

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	Mar. 20, 2019	Nov. 13, 2018	Aug. 30, 2018	Nov. 30, 2016	Oct. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Jan. 31, 2019	Sep. 26, 2018
Related Party Transactions (Textual)
Interest rate			5.00%
Sale of product						$ 360
Bad debt							$ 59
Principal amount			$ 750
Maturity date			Aug. 31, 2019
Accrued interest						$ 15
Lender advanced			$ 500
Description of amended and restated		The Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000. On December 29, 2018, the Lender advanced an additional $250 of funds to the Company. As of December 31, 2018, the Company recorded $1,000 as a liability on the consolidated balance sheets.
Lender advanced additional of funds									$ 250
Subsequent Event [Member]
Related Party Transactions (Textual)
Principal amount	$ 1,000
Advance from CEO Joe Mannello								$ 250
Description of securities purchase agreement	The Company entered into a securities purchase agreement with a group of accredited investors, including two members of the Company's board of directors, in a private placement for aggregate gross proceeds of $2.1 million, which includes the conversion of $250 of the principal amount of a $1.0 million promissory note previously issued by the Company to its chief executive officer.
RENS Technology Inc. [Member]
Related Party Transactions (Textual)
Sale of product					$ 116
Bad debt					$ 59
Percentage of sales agreement deposit				50.00%

Legal Proceedings (Details)

Legal Proceedings (Details) - RENS Technology Inc. [Member] $ in Thousands	Jan. 06, 2017USD ($)shares
Legal Proceedings (Textual)
Aggregate purchase of warrant	884,259
Aggregate purchase of investment | $	$ 20,250
Aggregate exchange for common stock	3,537,037

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 20, 2019	Jan. 15, 2019	Nov. 13, 2018	Feb. 03, 2017	Mar. 19, 2019	Jan. 31, 2019	Dec. 31, 2018	Aug. 30, 2018	Apr. 29, 2018	Apr. 23, 2018	Apr. 04, 2018	Jan. 19, 2018	Feb. 08, 2017	Oct. 26, 2016
Subsequent Event [Line Items]
Note payable, description			The Company amended and restated the Note to increase the maximum amount that may be drawn down under the Note from $750 to $1,000.
Sale of common stock, shares				500,000			882,649
Sale of purchase price per share				$ 4.25					$ 1.24	$ 1.38	$ 1.25	$ 2.111	$ 4.25	$ 2.144
Gross proceeds of common stock value				$ 2,125			$ 1,755
Principal amount								$ 750
Subsequent Event [Member]
Subsequent Event [Line Items]
Note payable, description		The Company sold 32,489 shares of common stock for $2.00 per share for gross proceeds of $65 in an at-the-market offering. On March 19, 2019 the Company sold 78,640 shares of common stock for $1.85 per share for gross proceeds of $145 in an at-the-market offering. As of the filing date of this Report, a total of 882,649 shares were sold under at-the market offerings for aggregate gross proceeds of $1,755.
Received net proceeds						$ 1,124
Advance from CEO Joe Mannello						$ 250
Sale of common stock, shares	1,438,356	32,489			78,640
Sale of purchase price per share	$ 1.46	$ 2			$ 1.85
Gross proceeds of common stock value	$ 2,100	$ 65			$ 145
Conversion of promissory note	250
Principal amount	$ 1,000